2023-07-18 08:37:26
Home Health Illness
Some experts, however, remain cautious regarding this new treatment, whose benefits remain “modest” and which has potential dangerous side effects.
Posted on 07/18/2023 10:37 Updated on 07/18/2023 11:39
Reading time: 1 min.
The premises of the Eli Lilly pharmaceutical laboratory in Indianapolis (United States), April 26, 2017. (DARRON CUMMINGS/AP / SIPA)
The authorization of a new drug once morest Alzheimer’s might take place this year in the United States. On Monday July 17, the full results of a large-scale clinical trial of donanemab were published and confirmed the ability of this treatment, developed by the pharmaceutical group Eli Lilly, to slow the progression of the disease in patients, especially when is taken very early. Donanemab, like lecanemab approved in May by the US Medicines Agency, is administered intravenously and attacks plaques in the brains of patients with Alzheimer’s disease, called amyloid plaques.
Three deaths during the trial
The clinical trial for Eli Lilly’s treatment was conducted in eight countries on more than 1,700 people aged 60 to 85 who had not yet reached an advanced stage of the disease. However, some experts remain cautious regarding this new treatment, the benefits of which remain “modest” and which has potential dangerous side effects, such as edema or cerebral hemorrhage. Especially since three deaths are probably linked to the treatment, according to the results of the trial published in the scientific journal Jama.
“The modest benefits would likely not be questioned by patients, clinicians or taxpayers” if these treatments were “low risk, low cost and simple to administer”, reacted several experts. The latter also criticized the low proportion of people of color included in the trial, when they are more affected by the disease. Collecting more data, including beyond 18 months, would therefore be necessary in order to better understand the benefits and risks of donanemab.
View comments
Share the article on social networks:
Share on Twitter Share on Facebook Share by email Share link
1689677223
#treatment #slows #progression #disease #results #clinical #trial
